Dei-Cas, Ignacio
Giliberto, Florencia
Luce, Leonela
Dopazo, Hernán
Penas-Steinhardt, Alberto
Funding for this research was provided by:
Novartis Pharma (CAIN457AAR02T)
Article History
Received: 24 January 2020
Accepted: 7 July 2020
First Online: 29 July 2020
Competing interests
: Dr Dei-Cas has received compensation as a speaker, consultant, and investigator for Novartis, Eli Lilly and Janssen. Dr Penas-Steinhardt has received compensation as a speaker for Novartis. Dr Florecina Giliberto, Dr. Leonela Luce and Dr. Hernán Dopazo declare no competing interest.